reports
- Jonathan Moreland
UPDATE — Pennant Completes Purchase of Tennessee, Georgia and Alabama ...
UPDATE — Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that on October 1, 2025, it acquired certain operations from UnitedHealth Group Incorporated (“UnitedHealth”). The operations were divested pursuant to UnitedHealth’s acquisition of Amedisys Inc. by UnitedHealth’s Optum unit. Pennant is purchasing divested...
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operation...
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that on October 1, 2025, it acquired certain operations from UnitedHealth Group Incorporated (“UnitedHealth”). The operations were divested pursuant to UnitedHealth’s and Amedisys Inc.’s (“Amedisys”) antitrust settlement with the United States Justice Department. Pe...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data D...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 monthsThe second dose of BPL-003 led to further reductions in MADRS scores from baseline, indicating that this regimen has the poten...
atai Life Sciences Awarded Grant from the National Institutes of Healt...
atai Life Sciences Awarded Grant from the National Institutes of Health 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder NEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that it has been awarded a multi-year, milestone-driven grant worth up to $11.4 million b...
Pennant Group to Participate in the 2025 Jefferies Healthcare Services...
Pennant Group to Participate in the 2025 Jefferies Healthcare Services Conference EAGLE, Idaho, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2025 Jefferies Healthcare Services Conference on September 29, 2025. Brent Guerisoli, Chief Executive Officer, John Gochnour, Chief Operating Officer, and Kirk Cheney, Executive Vice President, will participate in a fireside chat on September 29, 2025 at 1:15 p....
Pennant Announces Home Health Acquisition in Wyoming
Pennant Announces Home Health Acquisition in Wyoming EAGLE, Idaho, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that effective September 1, 2025, it has acquired a premier home health agency and outpatient therapy operation in Wyoming. Both businesses, which will continue operating as Healing Hearts Home Health and Healing Hearts Outpatient Therapy, will serve communities in Gillette and Moorcroft, expanding Pennant’s service area...
atai Life Sciences to Participate in September Investor Conferences
atai Life Sciences to Participate in September Investor Conferences NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences. Details of the Company’s participation are as follows: Cantor Global Healthcare Conference 2025 Format: Fireside ChatDate: Friday, September 5th at 8:35 a.m. ETLocation: New...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
MGNX MACROGENICS INC.
MERC MERCER INTERNATIONAL INC.
LOB LIVE OAK BANCSHARES
HTH HILLTOP HOLDINGS INC.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
CE CELANESE CORPORATION
QRHC QUEST RESOURCE HOLDING
HTLD HEARTLAND EXPRESS INC.
RSG REPUBLIC SERVICES INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
BSM BLACK STONE MINERALS LP
NTLA INTELLIA THERAPEUTICS INC.
CYRX CRYOPORT INC.
SD SANDRIDGE ENERGY INC.
ECIA ENCISION INC
UA UNDER ARMOUR
EOLS INC.
CCEL EVOLUS INC
ULBI CRYO-CELL INTERNATIONAL
AVTR ULTRALIFE
EPSN AVANTOR
ASAN INC.
OPCH EPSILON ENERGY LIMITED
MYO ASANA
ATAI OPTION CARE HEALTH INC
PFHC MYOMO
OPAL ATAI LIFE SCIENCES BV
CALC PROFRAC HLDG CORP
ET OPAL FUELS INC
PROP CALCIMEDICA INC.
FIP ENERGY TRANSFER LP
MDRR PRAIRIE OPERATING CO.
ECF FTAI INFRASTRUCTURE INC
LNW MEDALIST DIVERSIFIED REIT INC.
NUGN ELLSWORTH FUND LTD
EFOI LIGHT & WONDER INC.
SST LIVENTO GROUP
STRZ INC.
ENERGY FOCUS INC.
SYSTEM1 INC
STARZ ENTERTAINMENT CORP
- Jonathan Moreland
HTH HILLTOP HOLDINGS INC.
CE CELANESE CORPORATION
ASA ASA
ADC AGREE REALTY CORPORATION
HTLD HEARTLAND EXPRESS INC.
PLBC PLUMAS BANCORP
SMRT SMARTSPACE SOFTWARE
EOLS EVOLUS INC
GRNT GRANIT SKOPKE
MYO MYOMO
ATAI ATAI LIFE SCIENCES BV
PFHC PROFRAC HLDG CORP
MSDL MORGAN STANLEY DIRECT LENDING
DMA DESTRA MULTI ALTERNATIVE FUND
atai Life Sciences Reports Second Quarter 2025 Financial Results and R...
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects fo...
Pennant Reports Second Quarter 2025 Results
Pennant Reports Second Quarter 2025 Results Conference Call and Webcast scheduled for tomorrow, August 7, 2025 at 10:00 am MT EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted earnings per share of $0.20 for the second quarter of 2025. Pennant also reported adjusted diluted earnings per share of $0.27 for the quarter(1). Second Quarter Highlights Total revenue for the second quarter w...
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascam...
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpointInidascamine continues to exhibit a favorable safety and tolerability profileFull data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognif...
Pennant Announces Second Quarter 2025 Earnings Release and Call
Pennant Announces Second Quarter 2025 Earnings Release and Call EAGLE, Idaho, July 22, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its second quarter 2025 financial results on Wednesday, August 6, 2025. Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Thursday, August 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management...
Pennant Announces Home Health Acquisition in Southern California
Pennant Announces Home Health Acquisition in Southern California EAGLE, Idaho, July 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of a premier home health agency, GrandCare Health Services. The newly acquired agency, to be known as GrandCare Home Health, provides services in Los Angeles, Orange, Riverside and San Diego counties in California, and broadens Pennant’s service area in the region. “We are happy to welcome GrandCa...
atai Life Sciences Announces $50 Million Private Placement Financing
atai Life Sciences Announces $50 Million Private Placement Financing Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary...
- David Nierengarten
- Dennis Pak
- Martin Fan
atai Life Sciences and Beckley Psytech Announce Positive Topline Resul...
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of trea...
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of ...
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”). If the Acquisition is completed, there will be no Annual Meeting involving public stockholders. If the Acquisition is not completed, the Board of Directors will take s...
atai Life Sciences and Beckley Psytech to Combine Creating a Global Le...
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.